Zdrowie i gospodarka · 03/08/1998

FDA Approves Lower Dose of Milbemycin Oxime for Heartworm Prevention in Dogs and Puppies

The US Food and Drug Administration (FDA) has amended its animal drug regulations to reflect approval of a supplemental new animal drug application (NADA) filed by Novartis Animal Health US, Inc., allowing for the use of a lower dose of milbemycin oxime to prevent heartworm disease in dogs and puppies.